Analysts have returned from a visit to the drugmaker’s Indianapolis headquarters, reporting that Lilly is facing a number of headwinds, one of which will be warded off by doubling the firm’s production capacity for Mounjaro.
by ulrich quistgaard, translated by daniel pedersen
In an attempt to mitigate future financial challenges, Eli Lilly will double the production of its newest and highly sought-after type 2 diabetes drug, Mounjaro, reports industry media Endpoints News.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.